Investor Information

Overview

Sharp Therapeutics (“Sharp”, TSXV:SHRX) is a preclinical-stage life sciences company developing small molecule drugs for genetic diseases.

Sharp uses proprietary technologies to make possible the discovery and development of small molecule compounds that reverse the effect of protein mutation restoring the loss-of-function caused by gene mutation in genetic disease. These small molecules provide the functional benefit previously only achievable with large complex biologics: e.g. enzyme replacement, antibodies, gene therapy, cell therapy and antisense oligonucleotides.

By enabling small molecule discovery Sharp makes possible oral treatments for diseases previously treated only by injection/infusion or by other methods that are costly and inconvenient for patients. Small molecules are also more easily manufactured, and more safely administered to patients than novel biological therapies.

By focusing on genetic disease Sharp’s targets are all clinically validated, and the development, approval and reimbursement path for bringing these new medicines to market is well established. Importantly, because the cause of each genetic disease is known at the molecular level, Sharp will get a much earlier clinical read of efficacy, thus greatly accelerating clinical trials and improving their likelihood of success

Sharp explores strategic relationships to expand and accelerate its development pipeline and to speed the movement of our clinical compounds to patients.